Lilly Forteo
Executive Summary
FDA Endocrinologic & Metabolic Drugs Advisory Committee will review teriparatide (NDA 21-318) July 27 for the treatment of osteoporosis in post-menopausal women and in men (1"The Pink Sheet" May 14, In Brief). The committee will meet at 8 a.m. at the Holiday Inn in Bethesda, Md